GRL-0617 (C005B-309804)

Catalog No.: C005B-309804
Mfr. No.: SML2961-25MG
Mfr. Name: Sigma-Aldrich
Qty/UOM: 25
UOM: MG

Price: $827.03

List Price: $918.92

Biochem/physiol Actions GRL-0617 is a cell penetrant non-cytotoxic and potent inhibitor of the SARS-CoV -2 papain-like protease (SCoV2-PLpro) and SCoV-PLpro. GRL-0617 reversibly binds to SCoV2-PLpro and disrupts its interaction with

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

Current Stock:

Quantity:

Adding to cart… The item has been added

Description
Specifications

Biochem/physiol Actions

GRL-0617 is a cell penetrant non-cytotoxic and potent inhibitor of the SARS-CoV -2 papain-like protease (SCoV2-PLpro) and SCoV-PLpro. GRL-0617 reversibly binds to SCoV2-PLpro and disrupts its interaction with Interferon-stimulated gene 15 (ISG15). GRL-0617 poorly affects (> 100 μM) the activities of MERS PLpro, a series of cysteine proteases, including the human deubiquitinating enzymes HAUSP, USP18, UCH-L1, UCH-L3, and a papain-like protease (PLP2) from the human coronavirus NL63. GRL-0617 suppress SARS-CoV-2 infection and promote anti-viral immunity.

UPC:: 51321502
Condition:: New
Availability:: 3-5 Days
Weight:: 1.00 Ounces
HazmatClass:: No
MPN:: SML2961-25MG
CAS:: 1093070-16-6

Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."